Extreme risk category in the stratification of cardiovascular complications. Consensus Council of experts
- Authors: Expert C.1
-
Affiliations:
- Issue: Vol 26, No 4 (2019)
- Pages: 138-143
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/298036
- ID: 298036
Cite item
Open Access
Access granted
Abstract
The conclusion of the advisory board demonstrates the necessity of introducing a new risk category for cardiovascular complications: the extreme risk category. The article presents the analysis of the studies that were the basis for the introduction of this risk category. The following patients groups may be classified as an extreme risk category: combination of clinically significant atherosclerotic cardiovascular disease with diabetes mellitus type 2; atherosclerotic cardiovascular disease with cardiovascular complications occurred despite adequate lipid lowering therapy and/or achieved LDL cholesterol level <1.5 mmol/l. Management of extreme risk patients is discussed, that includes not only requirements of achievement of LDL cholesterol, blood pressure and HbA1c target levels, but also using of drugs with proved effectiveness in reducing cardiovascular risk.
Full Text
References
- Сергиенко И.В., Аншелес А.А., Кухарчук В.В. Дислипидемии, атеросклероз и ишемическая болезнь сердца: современные аспекты патогенеза, диагностики и лечения. 3 изд., перераб. и доп. М., 2018.
- Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VI пересмотр. Атеросклероз и дислипидемии. 2017;3(28):5-23.
- Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 8-й выпуск. Сахарный диабет 2017;20(1S):1-112.
- Whelton P.K., Carey R.M. The 2017 Clinical Practice Guideline for High Blood Pressure. JAMA. 2017;318(21):2073- 74.
- Jellinger P.S., Handelsman Y., Rosenblit P.D., et al. American Association of Clinical Endocrinologists and Ame55555rican College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract. 2017;23(Suppl. 2):1-87.
- Watts G.F., Gidding S., Wierzbicki A.S., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014;171(3): 309-25.
- de Boer I.H., Bakris G., Cannon C.P. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018;319(13):1319-20.
- de Zeeuw D., Anzalone D.A., Cain V.A., et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet. Diabet Endocrinol. 2015;3(3):81-190.
- Barter PJ., Waters D.D. Variations in time to benefit among clinical trials of cholesterol-lowering drugs. J Clin Lipidol. 2018 Apr 21. Doi: 10.1016/j. jacl.2018.04.006.
- Cannon C.P, Blazing M.A., Giugliano R.P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97.
- Sabatine M.S., Giugliano R.P, Keech A.C., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22.
- Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Cholesterol Treatment Trialists' (CTT) Collaboration. Lancet. 2010;376(9753):167-81.
- Boekholdt S.M., Hovingh G.K., Mora S., et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 201;64(5):485-94.
- Institute for Clinical and Economic Review. Alirocumab for High Cholesterol - Preliminary New Evidence Update. March 10, 2018.
- Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.
- Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22.
- Mitchell J.D., Brown D.L. Harmonizing the Paradigm With the Data in Stable Coronary Artery Disease: A Review and Viewpoint. J Am Heart Assoc. 2017;6(11).
- Al-Lamee R., Thompson D., Dehbi H.M., et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31-40.
- Brignole M., Auricchio A., Baron-Esquivias G., , et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur. Heart J. 2013;34(29):2281-329.
Supplementary files
